Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,518 across all filing types
Latest filing 2024-09-19 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
NOTIFICATION LETTER TO SHAREHOLDER AND CHANGE REQUEST FORM
Report Publication Announcement Classification · 95% confidence The document is a notification letter from CSPC Pharmaceutical Group Limited dated 20 September 2024. It announces the publication of the 2024 Interim Report and provides instructions for shareholders on how to access the report electronically or in printed form. The letter includes a change request form for shareholders to elect their preferred method of receiving future corporate communications. The document does not contain the actual interim financial report or substantive financial data but rather informs shareholders about the availability of the report and how to obtain it. This fits the definition of a Report Publication Announcement (RPA), which is an announcement regarding the timing, release, or publication of company reports, often stating the report is attached or available on the website. Therefore, the correct classification is RPA with high confidence.
2024-09-19 English
2024 INTERIM REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report 2024' and contains detailed financial statements such as condensed consolidated income statement, statement of comprehensive income, statement of financial position, statement of changes in equity, and statement of cash flows. It also includes management discussion and analysis, financial highlights for the six months ended 30 June 2024, and other substantive financial data. The length of the document is 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of interim dividend information and share buy-back details further supports that this is a comprehensive interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-09-19 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares for CSPC Pharmaceutical Group Limited. It includes detailed tables of share repurchases, prices, dates, and confirmations of compliance with listing rules. The content focuses on share repurchase activities and changes in capital structure rather than financial results, management changes, or regulatory certifications. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is substantial and contains detailed transactional data, not just an announcement or a brief summary, so it is not a report publication announcement or regulatory filing. Therefore, the appropriate classification is 'POS' (Transaction in Own Shares).
2024-09-17 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations that the repurchases were made in accordance with the relevant rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchase activity and changes in capital structure. This fits the definition of a 'Transaction in Own Shares' filing, which covers company buybacks or sales of its own shares. The document length is substantial and contains detailed transactional data, confirming it is the report itself, not just an announcement of a report. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2024-09-16 English
VOLUNTARY ANNOUNCEMENT - AMPHOTERICIN B LIPOSOME FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the drug registration approval of a new product, Amphotericin B Liposome for Injection. It is an announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. The document is relatively short (3080 characters) and does not contain financial data or detailed report content. It is not a report publication announcement since it does not mention any report being attached or published. The content focuses on product approval news, which fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-09-16 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares for CSPC Pharmaceutical Group Limited. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations that repurchases were made in accordance with exchange rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchases and capital changes. This fits the definition of a 'Transaction in Own Shares' filing, which covers company buybacks or sales of its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report publication.
2024-09-13 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.